Streetbeat News

Earnings

TDY

Teledyne Technologies Incorporated has projected its Q2 adjusted earnings per share (EPS) to be in the range of $4.40-$4.50, which is below the estimated $5.00.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 11:00 am

WNC

Wabash National (WNC) reaffirms its FY24 revenue outlook of $2.2B-$2.4B, aligning with a $2.25B estimate, and maintains its EPS guidance range of $2.00-$2.50, versus a $2.19 estimate. The company views 2024 as crucial for strategic advancement, focusing on strengthening its competitive position through its dealer network and the integration of digital solutions, including the development of the Wabash Marketplace digital platform.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 11:00 am

TDY

Teledyne Technologies reported Q1 orders totaling $1.43 billion, indicating strong demand for its products and services.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:58 am

TDY

Teledyne Technologies (NYSE:TDY) reported Q1 adjusted EPS of $4.55, missing the $4.63 estimate, and sales of $1.35B, below the $1.40B estimate. This represents a slight increase in EPS and a decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:56 am

WNC

Wabash National (NYSE:WNC) reported Q1 adjusted earnings of $0.39 per share, missing the $0.45 estimate, and sales of $515.28M, below the $516.85M estimate. This represents a 62.5% decrease in earnings and a 17.02% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:55 am

ALZN

BEEP

CONN

Insiders at Alzamend Neuro, Mobile Infrastructure, and Conn's have recently made significant stock purchases, signaling potential confidence in their companies' futures. Conn's reported a narrower Q4 loss than expected, Mobile Infrastructure is preparing for its Q1 2024 earnings release, and Alzamend Neuro received FDA approval to proceed with a PTSD study.

Portfolio Pulse from Avi Kapoor

April 24, 2024 | 10:54 am

BIIB

Biogen has reaffirmed its 2024 adjusted EPS guidance of $15.00-$16.00, indicating a 5% growth from 2023, aligning with a consensus of $15.48. The company anticipates a low- to mid-single digit percentage decline in total revenue compared to 2023 but expects its core pharmaceutical revenue to remain stable. Additionally, Biogen projects a low-double digit percentage growth in operating income and a mid-single digit percentage improvement in operating margin.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:53 am

AVY

Avery Dennison Corporation has revised its FY24 earnings guidance downwards, adjusting the reported earnings per share (EPS) forecast from $8.65-$9.15 to $8.60-$9.10. However, the company maintains its adjusted EPS outlook of $9.00 to $9.50, excluding an estimated $0.40 per share impact from restructuring charges and other items.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:52 am

BXMT

Blackstone Mortgage Trust reported its Q1 2024 distributable EPS prior to charge-offs at $0.65, surpassing the estimate of $0.43.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:52 am

EVR

Evercore (NYSE:EVR) reported Q1 2024 adjusted EPS of $2.13, surpassing the $2.09 estimate, but its sales of $587.328M fell short of the expected $636.381M. This represents a slight decrease in earnings and a modest increase in sales from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:51 am